{
    "clinical_study": {
        "@rank": "136229", 
        "arm_group": [
            {
                "arm_group_label": "Zinc", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "sodium", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Using orally administered zinc to patients already diagnosed with the pre-cancerous\n      condition, Barrett's Esophagus, this study is asking two questions:\n\n        1. can this zinc administration cause molecular-level changes in the Barrett's tissue?\n\n        2. are the changes measured indicative of chemopreventive action by zinc regarding cancer\n           progression?"
        }, 
        "brief_title": "Effect of Zinc on Barrett's Metaplasia", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Barrett's Metaplasia", 
        "condition_browse": {
            "mesh_term": [
                "Barrett Esophagus", 
                "Metaplasia"
            ]
        }, 
        "detailed_description": {
            "textblock": "14 days prior to already-scheduled upper endoscopy (EGD) procedures for routine surveillance\n      of Barrett's tissue, patients who have given written, informed consent are randomized\n      (sealed envelope method) and placed on an oral dose of zinc gluconate (26.6 mg zinc BID) or\n      a placebo (molar equivalent of sodium gluconate BID) for 14 days.  At the time of endoscopy,\n      4 biopsies are taken (and pooled) from the Barrett's tissue and 4 from proximal normal\n      esophageal tissue.  Biopsies are flash frozen for later analyses by atomic absorption\n      spectroscopy, PAGE and Western immunoblot or RNA microarray."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:ages 18-80; prior diagnosis of Barrett's esophagus -\n\n        Exclusion Criteria:unable to provide written, informed consent; prior history of Barrett's\n        dysplasia or esophageal adenocarcinoma; drug exclusions: hormone replacement therapy,\n        cholestyramine, amiloride diuretics, oral quinolone antibiotics, glucocorticoids,\n        corticosteroids, anticoagulants (other than aspirin)\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984580", 
            "org_study_id": "F/N-R-11-3038L"
        }, 
        "intervention": {
            "arm_group_label": "Zinc", 
            "description": "26.6 mg zinc BID (as zinc gluconate)", 
            "intervention_name": "zinc gluconate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Zinc"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Barrett's esophagus", 
            "Esophagus", 
            "Adenocarcinoma"
        ], 
        "lastchanged_date": "November 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Wynnewood", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19096"
                }, 
                "name": "Lankenau Institute for Medical Research"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Zinc on Barrett's Metaplasia", 
        "overall_contact": {
            "email": "mullinj@mlhs.org", 
            "last_name": "James M Mullin, Ph.D.", 
            "phone": "484-476-2708"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Changes in zinc-regulated cellular proteins within Barrett's tissue", 
            "safety_issue": "No", 
            "time_frame": "in biopsy tissue after 14 days of Zn exposure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984580"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Main Line Health", 
            "investigator_full_name": "James M. Mullin, Ph.D.", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Changes in cellular microRNA profile; changes in protein cancer biomarkers", 
            "safety_issue": "No", 
            "time_frame": "in biopsy tissue after 14 days of Zn exposure"
        }, 
        "source": "Main Line Health", 
        "sponsors": {
            "collaborator": {
                "agency": "Sharpe-Strumia Research Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Main Line Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}